NEURL4: A Potential Drug Target and Biomarker (G84461)

Target Name: NEURL4

NCBI ID: G84461

NEURL4

NEURL4: A Potential Drug Target and Biomarker

Neuralized-like protein 4 (NEURL4) is a protein that has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, pain, and inflammation. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has gained significant attention in the scientific community.

NEURL4 is a member of the superfamily of cytoskeletal proteins known as the neuropilin family. This family of proteins plays a critical role in the structure and function of neural cells, including the development and maintenance of the neuronal network. NEURL4 is characterized by a unique molecular architecture that consists of a long cytoplasmic tail, a short transmembrane region, and a unique N-terminus that contains a conserved glycine-rich region.

One of the key features of NEURL4 is its ability to interact with various signaling molecules, including tyrosine and chemokines. This interaction with these molecules has led to the identification of several potential drug targets for NEURL4.

The neurodegenerative disorder, Alzheimer's disease, is a leading cause of dementia and affects millions of people worldwide. The hallmark of Alzheimer's disease is the accumulation of neurofibrillary tangles and senile plaques in the brain. These tangles and plaques are thought to contribute to the neurodegeneration that occurs in the disease.

NEURL4 has been shown to be involved in the regulation of neurofibrillary tangles and senile plaques in the brain. Studies have shown that NEURL4 levels are decreased in the brains of individuals with Alzheimer's disease, and that inhibition of NEURL4 has been shown to protect against neurofibrillary tangles and senile plaques in animal models of the disease.

In addition to its potential role in Alzheimer's disease, NEURL4 has also been shown to be involved in the development and maintenance of other neurodegenerative disorders, including Parkinson's disease and Huntington's disease.

The pain and inflammation that many individuals experience can also be attributed to neurodegenerative disorders. NEURL4 has been shown to be involved in the regulation of pain and inflammation in the brain, and has been identified as a potential biomarker for monitoring the effectiveness of pain and inflammation treatments.

The identification of NEURL4 as a potential drug target and biomarker has significant implications for the development of new treatments for neurodegenerative disorders. By targeting NEURL4 with small molecules or antibodies, researchers may be able to reduce the production of neurofibrillary tangles and senile plaques, improve brain function, and alleviate symptoms of neurodegenerative disorders.

In conclusion, NEURL4 is a protein that has the potential to be a drug target and biomarker for various neurodegenerative disorders. Its unique structure and function, as well as its involvement in the regulation of neurofibrillary tangles and senile plaques, make it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of NEURL4 in neurodegenerative disorders and to develop effective treatments.

Protein Name: Neuralized E3 Ubiquitin Protein Ligase 4

Functions: Promotes CCP110 ubiquitination and proteasome-dependent degradation. By counteracting accumulation of CP110, maintains normal centriolar homeostasis and preventing formation of ectopic microtubular organizing centers

The "NEURL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEURL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets